-
Annals of Allergy, Asthma & Immunology... Jul 2020
Topics: Allergy and Immunology; Humans; Primary Prevention; Vaccines
PubMed: 32564925
DOI: 10.1016/j.anai.2020.03.031 -
Indian Heart Journal 2019Aspirin is one of the oldest and most commonly used cardiovascular drugs. Despite there being high-quality evidence supporting the use of aspirin for patients with known... (Review)
Review
Aspirin is one of the oldest and most commonly used cardiovascular drugs. Despite there being high-quality evidence supporting the use of aspirin for patients with known cardiovascular disease, a definitive consensus regarding its use for patients at risk for cardiovascular disease (and without established cardiovascular disease) has never been reached. Many randomized control trials have produced conflicting results, and consequently, society guidelines have issued differring recommendations. Three major trials were published in 2018, which supplement the existing data on aspirin's role in primary prevention and provide further guidance on this contentious issue. This article reviews the history of aspirin through the last two decades, with special emphasis on these new trials.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention
PubMed: 31280821
DOI: 10.1016/j.ihj.2019.04.001 -
The American Journal of Medicine Jan 2021
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Sex Factors
PubMed: 32941847
DOI: 10.1016/j.amjmed.2020.08.014 -
Preventive Medicine Jul 2015Anxiety disorders are the most prevalent psychiatric disorders in primary care and have significant social, economic, and interpersonal costs. Primary care is an ideal... (Review)
Review
OBJECTIVE
Anxiety disorders are the most prevalent psychiatric disorders in primary care and have significant social, economic, and interpersonal costs. Primary care is an ideal setting to prevent the appearance of anxiety disorders. The aim of this study was to evaluate the efficacy and cost-effectiveness of primary prevention interventions in anxiety disorders in the adult population receiving primary health care.
METHODS
A literature search was carried out in four databases-PubMed, PsycInfo, Cochrane, and Web of Science-from January 1980 to November 2013. Clinical trials and systematic reviews published in English and non-English languages and that evaluated the efficacy and/or cost-effectiveness of interventions of primary prevention for anxiety in primary care in the general adult population were included. Risk of bias was assessed by the Cochrane Risk Bias Tool and Overview Quality Assessment Questionnaire.
RESULTS
No high-quality research was identified that studied primary prevention of anxiety disorders in the adult population in the primary care setting. The few studies that exist focus on the child-adolescent population or on other types of interventions, usually as secondary prevention.
CONCLUSION
This study emphasizes the need for the development of high-quality clinical trials on the prevention of anxiety disorders in primary care.
Topics: Anxiety Disorders; Humans; Mental Health; Primary Health Care; Primary Prevention
PubMed: 25456801
DOI: 10.1016/j.ypmed.2014.10.015 -
Indian Heart Journal 2020
Topics: Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention
PubMed: 32861373
DOI: 10.1016/j.ihj.2020.07.021 -
Clinics in Geriatric Medicine Feb 2018Evidence for preventive screening and therapeutic intervention for primary prevention of cardiovascular disease is limited for older adults. In this article, we review... (Review)
Review
Evidence for preventive screening and therapeutic intervention for primary prevention of cardiovascular disease is limited for older adults. In this article, we review screening and prevention strategies, including lifestyle, modifiable risk factors, and medications, that may be considered in older adults, with a focus on those ≥75 years, accounting for age, frailty and functional status, medical conditions, and life expectancy.
Topics: Aged; Cardiovascular Diseases; Healthy Lifestyle; Humans; Life Expectancy; Primary Prevention; Risk Factors
PubMed: 29129219
DOI: 10.1016/j.cger.2017.08.003 -
The Journal of Family Practice Oct 2020High mortality from VTE makes primary prevention appealing. Guidelines and assessment tools offer a variety of patient-specific strategies and agents.
High mortality from VTE makes primary prevention appealing. Guidelines and assessment tools offer a variety of patient-specific strategies and agents.
Topics: Anticoagulants; Hormonal Contraception; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Risk Factors; Venous Thromboembolism
PubMed: 33175919
DOI: No ID Found -
International Journal of Infectious... Nov 2012The efficacy of probiotics for the prevention of Clostridium difficile infection (CDI) is highly controversial, particularly with regard to the prevention of recurrent... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
The efficacy of probiotics for the prevention of Clostridium difficile infection (CDI) is highly controversial, particularly with regard to the prevention of recurrent CDI. We hypothesize that primary prevention of CDI among patients receiving antibiotics might be a more achievable goal for probiotics than prevention in patients with previous CDI where the host flora is markedly altered.
METHODS
We conducted a literature search for randomized, placebo-controlled efficacy studies of probiotic use among adults receiving antibiotics, in which CDI was one of the outcomes measured. In addition, we conducted meta-analyses of probiotics that were included in more than one randomized trial.
RESULTS
Eleven studies were identified; most were seriously underpowered to determine the efficacy of probiotics in the prevention of CDI. Two showed significantly lower rates of CDI among the probiotic recipients. A meta-analysis of three studies that used the probiotic combination Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R and a combined analysis of those studies with four studies that used Saccharomyces boulardii, showed lower CDI rates in recipients of probiotics compared with recipients of placebo (risk ratio=0.39; 95% confidence interval 0.19-0.79).
CONCLUSIONS
While potential flaws in study design were identified, a review of the available literature suggests that the primary prevention of CDI with specific probiotic agents may be achievable. Additional studies of sufficient size and with rigorous design are needed to confirm these findings.
Topics: Clostridioides difficile; Clostridium Infections; Humans; Primary Prevention; Probiotics; Randomized Controlled Trials as Topic
PubMed: 22863358
DOI: 10.1016/j.ijid.2012.06.005 -
Stroke Feb 2007
Review
Topics: Delivery of Health Care; Humans; Preventive Health Services; Primary Prevention; Stroke
PubMed: 17204675
DOI: 10.1161/01.STR.0000254717.89942.67 -
Annals of the New York Academy of... Oct 1993
Review
Topics: Adult; Child; Child, Preschool; Female; Humans; Male; Mexican Americans; Nutritional Sciences; Obesity; Parents; Primary Prevention; United States
PubMed: 8267304
DOI: 10.1111/j.1749-6632.1993.tb18845.x